Genmab and AbbVie Report Positive Phase 3 Trial Results for Epkinly in B-cell Lymphoma
Genmab (GMAB) and AbbVie (ABBV) announced topline results from a phase 3 clinical trial showing that their experimental treatment, Epkinly (epcoritamab), combined with the standard R-CHOP regimen significantly improved progression-free survival in patients with B-cell lymphoma. The data supports its potential as a first-line therapy for this type of cancer. The results are seen as promising and could lead to regulatory submissions or label expansions, potentially increasing Epkinly's market reach if approved. Both companies have been collaborating on the development of Epkinly since 2019 under an agreement that includes co-commercialization rights in certain regions.
